Cefalexin

头孢氨苄

Report date: 2022/05/11 12:45:48
NME

Base Information

Drug NameCefalexin
Drug Alias Name头孢菌素ⅣCephalexin monohydrate头孢立新Cefalexina头孢氨苄霉素 +[16] 
ClassificationSmall molecules > Heterocyclic drugs > AntibioticsSmall molecules > Heterocyclic drugs > Antibiotics > β-lactam antibiotics > Cephalosporins antibiotics
Mechanisms of ActionBacterial penicillin-binding protein inhibitorsCell wall inhibitors
TargetsBacterial penicillin-binding protein
Therapy Area/IndicationsAcute bacterial skin and skin structure infectionsProstatitisOtitis Media +[10] 
Global Approved IndicationsAcute bacterial skin and skin structure infectionsProstatitisOtitis Media +[7] 
Approved Indications in ChinaBacterial Infections
Original Approved Country/TerritoryUnited States
Original Approved Date1971/01/04
Country/TerritoryCanadaUnited StatesPakistan +[5] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of California San FranciscoThe University Of British ColumbiaMaoxiang Group (Tianjin) Pharmaceutical Co Ltd
Inactive CompaniesEli Lilly And CompanyPragma Pharmaceuticals LlcAga Khan University
Active IndicationsCystic FibrosisBreast NeoplasmsBacterial Infections
Inactive IndicationsAcute bacterial skin and skin structure infectionsProstatitisOtitis Media +[7] 

Other Information

ATC CodeJ01DB01
Related LinksWikipediaDrugBankKEGG